A study of anti-SARS-CoV-2 antibodies among healthcare personnel and the general population

Figures & data

Table 1. Seropositivity levels of healthcare workers and the general population.

Seropositivity	General population, n = 124 (December 2021)	General population, n = 113 (February 2023)	Healthcare workers, n = 104 (February 2023)
Anti-S1-IgG	70% (95% CI: 0.62–0.78)	78% (95% CI: 0.70–0.85)	99% (95% CI: 0.97–1.00)
Anti-NCP-IgG	10% (95% CI: 0.04–0.15)	48% (95% CI: 0.39–0.57)	56% (95% CI: 0.46–0.65)
Anti-S1-IgA	79% (95% CI: 0.72–0.86)	88% (95% CI: 0.82–0.94)	99% (95% CI: 0.97–1.00)
Neutralization antibodies	68% (95% CI: 0.60–0.76)	88% (95% CI: 0.82–0.94)	98% (95% CI: 0.95–1.00)

Figure 1. Comparison of IgA and IgG (anti-Spike protein and anti-Nucleoprotein) class antibodies in the general population and healthcare workers (HCWs) in February 2023. The statistical differences were determined by the Kruskal–Wallis test (**p < 0.005, ****p < 0.0001, ns = non-significant).

Figure 2. Comparison of IgA and IgG (anti-Spike protein and anti-Nucleoprotein) class antibodies in the general population in December 2021 and February 2023. The statistical differences were determined by the Kruskal–Wallis test (* p < 0.05, ** p < 0.005, ***p < 0.0005).

Figure 3. Comparison of neutralizing antibodies between the studied groups—the general population (December 2021 and February 2023) and healthcare workers (HCWs). The statistical differences were determined by the Kruskal–Wallis test (**p < 0.005, ****p < 0.0001).

Data availability statement

The data that support the findings of this study are available on request from the corresponding authors.